ClinicalTrials.gg
RecruitingNCT06338904SOLPROSU50+Updated May 5, 2026

Brief Problem-solving Intervention in Different Formats for the Prevention of Suicide in Adults Over 50

An interventional study of Problem-solving-based psychological intervention in Suicide, sponsored by University of Santiago de Compostela. Recruiting at 1 site in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Primary conditionSuicide(the registry's first term)UnverifiedIs this wrong?Suicide is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by University of Santiago de Compostela · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Sep 2023, registered Mar 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Suicide represents a personal tragedy and an enormous global public health problem. One of the most vulnerable groups is adults 50 years and older. Despite this stage of life is particularly amenable to the implementation of targeted suicide prevention strategies, we have few studies of the efficacy of psychological interventions, those that do exist have methodological limitations, and none were implemented in formats other than face-to-face, which limits their accessibility. There is a need for brief psychological interventions that can be administered in both face-to-face and remote formats, do not require long training periods, and are effective in different contexts: for example, problem-solving therapy. The main objective of this project is to evaluate the efficacy of a brief problem-solving psychological intervention for targeted suicide prevention in people aged 50 years and older, administered in face-to-face, conference call, and smartphone app formats. A randomized controlled trial will be performed. Participants will be recruited through healthcare centers in the Autonomous Community of Galicia (Spain). To be included, participants must: (a) be at least 50 years old, (b) reside in Galicia, and (c) present suicidal ideation. Subjects will be excluded if they: (a) present serious mental health or medical disorders; (b) have begun receiving psychological or psychopharmacological treatment in the previous two months or are participating in other suicide prevention research; (c) do not have an appropriate mobile device or sufficient fluency to communicate in Spanish, or have problems that make it impossible to participate; or (d) plan to move in the next 18 months. At pre-intervention information will be collected on sociodemographic, family, personal history, current suicide risk and other clinical variables. 212 participants will be randomly assigned to (1) a problem-solving-based psychological intervention delivered face-to-face (PSPI-FF; experimental group 1); (2) a problem-solving-based psychological intervention delivered via telephone conference call (PSPI-CC; experimental group 2); (3) a problem-solving-based psychological intervention delivered via a smartphone app (PSPI-A; experimental group 3); or (4) a usual care control group (UCCG). Participants in the experimental groups will complete the six sessions/modules of the interventions. Finally, subjects in all groups will be evaluated at post-intervention and 3, 6 and 12-month follow-ups.

02

Conditions studied

  • Suicide

Browse trials for

Keywords

  • randomized controlled trial
  • prevention
  • problem solving
  • conference call
  • App
  • Adults over 50
03

In context

Suicide Unverified

609 studies on the registry are indexed under Suicide; 163 are open to participants now.

This study's planned enrollment of 212 is above the median of 104 across 492 interventional studies indexed under Suicide.

Browse Suicide studies →

Lead sponsor

University of Santiago de Compostela is the lead sponsor of 60 studies on the registry; 12 are open to participants now.

Compared within Suicide, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 50 years old
  • Reside in Galicia
  • Present suicidal ideation

Exclusion criteria

Exclusion Criteria:

  • Present serious mental health or medical disorders
  • Have begun receiving psychological or psychopharmacological treatment in the previous two months or are participating in other suicide prevention research
  • Do not have an appropriate mobile device or sufficient fluency to communicate in Spanish, or have problems that make it impossible to participate
  • Plan to move in the next 18 months.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Problem-solving-based psychological intervention delivered in a face-to-face format (PSPI-FF)

    Participants in this group will receive a problem-solving intervention for suicide prevention in a face-to-face format. The intervention will consist of 6 sessions, approximately 90 minutes in duration each, once a week, in a group format, in person.

    Behavioral: Problem-solving-based psychological intervention

  • Experimental
    Problem-solving-based psychological intervention delivered via telephone conference call (PSPI-CC)

    Participants in this group will receive the intervention described in a teleconference call format, with the same duration, contents, and structure.

    Behavioral: Problem-solving-based psychological intervention

  • Experimental
    Problem-solving-based psychological intervention delivered via a smartphone app (PSPI-A)

    Participants in this group will receive the intervention described adapted to be administered through a smartphone app, with equivalent duration, content, and structure (approximately 90 minutes to complete each of the 6 modules).

    Behavioral: Problem-solving-based psychological intervention

  • No intervention
    Usual care (UCCG)

    Participants in this group will receive usual care. Usual treatment will include individual and group psychotherapy and/or psychiatric medication as determined by the health professionals they are currently consulting, whether in public or private facilities.

Interventions

  • BehavioralProblem-solving-based psychological intervention

    The intervention will include training in the components of the problem-solving model and other behavioral and cognitive skills such as detecting warning signals, monitoring mood, relaxation techniques, self-reinforcement, strategies for acting in crisis situations, engaging in enjoyable activities, mindfulness meditation techniques, or strategies for reframing irrational thoughts. It will be developed from the problem-solving model (D'Zurilla and Nezu, 1982) and will reference the indicated prevention program for depression (Vázquez et al., 2015), which has shown efficacy in reducing depressive symptoms and preventing the onset of depression episodes (Otero et al., 2015; Vázquez et al., 2013), with results on symptomatology maintained at 8 years (López et al., 2020); and the indicated prevention intervention that demonstrated efficacy in reducing suicide risk (Xavier et al., 2019).

06

What researchers measure

Primary outcomes

  1. Change from baseline suicidal ideation to post-treatment (7 weeks), and follow-ups at 6 and 12 months.

    Suicidal ideation will be assessed using the Suicidal Ideation Scale (SSI; Beck et al., 1979), a semi-structured scale of 19 items with an internal consistency (Kuder-Richardson coefficient \[KR-20\]) of .89 and an inter-rater reliability (k) of .83.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  2. Change from baseline suicidal ideation to post-treatment (7 weeks), and follow-ups at 6 and 12 months.

    Aditionally, the severity of ideation and suicidal behavior over the last month will be assessed using the Columbia Scale for assessing suicide risk (C-SSRS; Posner et al., 2011). It consists of a semi-structured interview with good convergent and discriminant validity and high sensitivity (100.0%) and specificity (99.4%) for the classification of suicidal behavior; the ideation intensity subscale showed a Cronbach's alpha of .73-.95.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

Secondary outcomes

  1. Change from baseline hopelessness to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    Hopelessness will be assessed with the Beck Hopelessness Scale (HS; Beck et al., 1974), a self-administered instrument of 20 items with a range from 0 to 20. Higher scores mean higher hopelessness. It has an internal consistency (Kuder-Richardson 20 \[KR-20\]) of .93.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  2. Change from baseline anxiety and depressive symptoms to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    Anxiety and depression symptoms will be assessed with the General Health Questionnaire (GHQ-12; Goldberg \& Williams, 1988), a self-administered questionnaire of 12 items designed to screen for non-psychotic psychiatric morbidity, with a range from 0 to 12. Higher scores mean higher anxiety and depressive symptoms. Its internal consistency (Cronbach's alpha) is .86 for individuals under 65 years of age and .90 for individuals aged 65 years or older.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  3. Change from baseline reasons for living to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    Deterrent reasons for attempting suicide will be assessed through the Reasons for Living Inventory (RFL; Linehan et al., 1983), a self-administered instrument of 48 items across six subscales, with a range from 48 to 288. Higher scores mean that individuals exhibit higher reasons for living. Internal consistencies (Cronbach's alphas) range from .72 to .89.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  4. Change from baseline impulsivity to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    Impulsivity will be assessed using the Barratt Impulsiveness Scale (BIS-11; Patton et al., 1995), a self-administered instrument of 30 items, with a range from 30 to 120. Higher scores mean higher impulsivity. Its internal consistencies (Cronbach's alphas) range from .79 to .82.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  5. Change from baseline problem-solving skills to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    Problem-solving skills will be assessed with the Revised Social Problem-Solving Inventory (SPSI-R; D'Zurilla et al., 1997), an inventory of 52 items with a range from 0 to 208, and an internal consistency (Cronbach's alpha) ranging from .68 to .92.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  6. Change from baseline social support to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    Social support will be evaluated with the DUKE-UNC Functional Social Support Questionnaire (Duke-UNC-11; Broadhead et al., 1988), an 11-item questionnaire with a range from 11 to 55 and an internal consistency (Cronbach's alpha) of .90. Higher scores mean higher social support.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  7. Change from baseline syndrome of clinical anger to post-treatment (7 weeks), and follow-ups at 6 and 12 months

    The anger syndrome will be assessed with the Clinical Anger Scale (CAS; Snell et al., 1995), a self-administered instrument of 21 items with a range from 0 to 63, and an internal consistency (Cronbach's alpha) of .94. Higher scores correspond to greater clinical anger.

    Time frame: Pre- and post-intervention (7 weeks) with follow-ups at 3, 6 and 12 months

  8. Treatment adherence

    Treatment adherence will be assessed by recording the number of sessions attended or modules completed by each participant, and the number of intersession tasks completed.

    Time frame: During the intervention sessions (6 weeks)]

  9. Satisfaction with the service received

    Satisfaction with the intervention will be evaluated using the Client Satisfaction Questionnaire (CSQ-8; Larsen et al., 1979), an 8-item scale whose total score varies from 8 to 32, where a higher score indicates greater satisfaction with the service received. It has an internal consistency (Cronbach's alpha) of .80.

    Time frame: Post-intervention (7 weeks)

Other outcomes

  1. Sociodemographic, familial, personal history, and current suicide risk variables

    These variables will be assessed using a hetero-administered questionnaire, developed ad hoc for this study, following the recommended criteria in the Clinical Practice Guideline for the Prevention and Treatment of Suicidal Behavior (Grupo de Trabajo de la Guía de Práctica Clínica de Prevención y Tratamiento de la Conducta Suicida, 2012/2020). This questionnaire will include information on: sex, age, marital status, living arrangements, rural/urban setting, education level, main activity, family monthly income, characteristics of suicidal ideation (e.g., potential plans, access to lethal means, intent to die, previous suicide attempts); present/past risk factors (e.g., risk factors related to psychological and psychiatric problems, family history of suicidal behavior and mental disorder, history of physical abuse or sexual abuse); and health and psychosocial stress factors (e.g., presence of chronic illness, financial problems).

    Time frame: Pre-intervention.

07

Study locations

1 of 1 sites recruiting
  • Research Group on Mental Health and Psychopatology
    Santiago de Compostela, A Coruña 15782, Spain
    Recruiting
    • Fernando L. Vázquez González, Dr. · Contactfernandolino.vazquez@usc.es · 881811000
    • Ángela J. Torres Iglesias, MD, PhD. · Principal investigator
    • Miguel A. Simón López, PhD. · Sub investigator
    • Ana M. Bueno Palomino, PhD. · Sub investigator
    • Elena Andrade Fernández, PhD. · Sub investigator
    • Vanessa Blanco Seoane, PhD. · Sub investigator
    • Patricia Otero Otero, PhD. · Sub investigator
    • Manuel Arrojo Romero, MD, PhD. · Sub investigator
    • Mario Páramo Fernández, MD, PhD. · Sub investigator
08

References and documents

Publications

  • D'Zurilla TJ, Nezu, A. Social problem solving in adults. In: Kendall PC (editor). Advances in cognitive-behavioral research on therapy. New York: Academic Press; 1982. vol. 1, p. 202-74.
  • Vázquez FL, Otero P, Blanco V, Torres AJ. Terapia de solución de problemas para la depresión: una breve guía práctica en grupo. Madrid: Alianza Editorial. 2015.
  • Otero P, Smit F, Cuijpers P, Torres A, Blanco V, Vazquez FL. Long-term efficacy of indicated prevention of depression in non-professional caregivers: randomized controlled trial. Psychol Med. 2015 May;45(7):1401-12. doi: 10.1017/S0033291714002505. Epub 2014 Oct 21. PubMed 25331992 ↗
  • Vazquez Gonzalez FL, Otero Otero P, Torres Iglesias A, Hermida Garcia E, Blanco Seoane V, Diaz Fernandez O. A brief problem-solving indicated-prevention intervention for prevention of depression in nonprofessional caregivers. Psicothema. 2013 Feb;25(1):87-92. doi: 10.7334/psicothema2012.89. PubMed 23336549 ↗
  • Lopez L, Smit F, Cuijpers P, Otero P, Blanco V, Torres A, Vazquez FL. Problem-solving intervention to prevent depression in non-professional caregivers: a randomized controlled trial with 8 years of follow-up. Psychol Med. 2020 Apr;50(6):1002-1009. doi: 10.1017/S0033291719000916. Epub 2019 Apr 24. PubMed 31017076 ↗
  • Xavier A, Otero P, Blanco V, Vazquez FL. Efficacy of a problem-solving intervention for the indicated prevention of suicidal risk in young Brazilians: Randomized controlled trial. Suicide Life Threat Behav. 2019 Dec;49(6):1746-1761. doi: 10.1111/sltb.12568. Epub 2019 Jun 25. PubMed 31237377 ↗
  • Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979 Apr;47(2):343-52. doi: 10.1037//0022-006x.47.2.343. No abstract available. PubMed 469082 ↗
  • Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704. PubMed 22193671 ↗
  • Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol. 1974 Dec;42(6):861-5. doi: 10.1037/h0037562. No abstract available. PubMed 4436473 ↗
  • Goldberg D, Williams P.. A user's guide to the General Health Questionnaire. Windsor: NFER-Nelson. 1988.
  • Linehan MM, Goodstein JL, Nielsen SL, Chiles JA. Reasons for staying alive when you are thinking of killing yourself: the reasons for living inventory. J Consult Clin Psychol. 1983 Apr;51(2):276-86. doi: 10.1037//0022-006x.51.2.276. No abstract available. PubMed 6841772 ↗
  • Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995 Nov;51(6):768-74. doi: 10.1002/1097-4679(199511)51:63.0.co;2-1. PubMed 8778124 ↗
  • D'Zurilla TJ, Nezu AM, Maydeu-Olivares A.Manual for the social problem solving inventory-revised. North Tonawanda, NY: Multi-Health Systems. 1997.
  • Broadhead WE, Gehlbach SH, de Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care. 1988 Jul;26(7):709-23. doi: 10.1097/00005650-198807000-00006. PubMed 3393031 ↗
  • Snell WE Jr, Gum S, Shuck RL, Mosley JA, Hite TL. The Clinical Anger Scale: preliminary reliability and validity. J Clin Psychol. 1995 Mar;51(2):215-26. doi: 10.1002/1097-4679(199503)51:23.0.co;2-z. PubMed 7797645 ↗
  • Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207. doi: 10.1016/0149-7189(79)90094-6. No abstract available. PubMed 10245370 ↗
  • Grupo de Trabajo de la Guía de Práctica Clínica de Prevención y Tratamiento de la Conducta Suicida Guía de práctica clínica de prevención y tratamiento de la conducta suicida [Clinical Practice Guideline for the Prevention and Treatment of Suicidal Behavior] (Ed. Rev. 2020).Santiago de Compostela: Plan de calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad, Agencia de Evaluación de Tecnologías Sanitarias de Galicia (avaliat-t). 2012.
  • Vazquez FL, Torres AJ, Blanco V, Bouza Q, Otero P, Andrade E, Simon MA, Bueno AM, Arrojo M, Paramo M, Fernandez A. Brief psychological intervention for suicide prevention based on problem-solving applied in different formats to people over 50 years old: protocol for a randomized controlled trial. BMC Psychiatry. 2024 Sep 27;24(1):628. doi: 10.1186/s12888-024-06076-5. PubMed 39334120 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2026, 32 months after the start.

Of 310 non-industry interventional studies with no phase under Suicide, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 54. This study's planned 32 months is close to that.

Counting every sponsor, half of 321 studies reached it within 30 months; a quarter within 15 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2024
First posted
Apr 1, 2024
StartActual
Sep 1, 2023
Primary completionEst.
May 31, 2026
CompletionEst.
May 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06338904
Lead sponsor
University of Santiago de Compostela
Collaborators
Ministry of Science and Innovation, Spain
Responsible party
Fernando Lino Vázquez González (Full Professor, University of Santiago de Compostela) — Principal investigator
First posted
Apr 1, 2024
Start date
Sep 1, 2023
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Fernando L. Vázquez González, PhD.
Contact
fernandolino.vazquez@usc.es
(00 34) 881811000 ext. 13705
Fernando L. Vazquez González, PhD.
principal investigator · University of Santiago de Compostela
Ángela J. Torres Iglesias, PhD.
principal investigator · University of Santiago de Compostela

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion